For examples, Dalerba et al. found that CDX2 is a prognostic biomarker and that CDX2 deletion is associated with poor prognosis in stage II or III colorectal cancer patients (Dalerba et al., 2016). The gene discussed is CDX2; the disease is colorectal cancer.